Cargando…
Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF pati...
Autores principales: | Aono, Yuya, Nakamura, Yutaro, Kono, Masato, Nakamura, Hidenori, Yokomura, Koshi, Imokawa, Shiro, Toyoshima, Mikio, Yasui, Hideki, Hozumi, Hironao, Karayama, Masato, Suzuki, Yuzo, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Inui, Naoki, Suda, Takafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495940/ https://www.ncbi.nlm.nih.gov/pubmed/32928050 http://dx.doi.org/10.1177/1753466620953783 |
Ejemplares similares
-
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
por: Suzuki, Yuzo, et al.
Publicado: (2021) -
Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
por: Suzuki, Yuzo, et al.
Publicado: (2021) -
Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study
por: Koyauchi, Takafumi, et al.
Publicado: (2022) -
Assessment of malnutrition-related risk in patients with idiopathic pleuroparenchymal fibroelastosis
por: Suzuki, Yuzo, et al.
Publicado: (2023) -
Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study
por: Suzuki, Takahito, et al.
Publicado: (2021)